Biostem Technologies Stock Analysis
| BSEM Stock | USD 6.22 0.06 0.96% |
Biostem Technologies' financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Biostem Technologies' financial risk is the risk to Biostem Technologies stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that Biostem Technologies' debt-to-equity ratio measures a OTC Stock's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Biostem Technologies is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Biostem Technologies to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Biostem Technologies is said to be less leveraged. If creditors hold a majority of Biostem Technologies' assets, the OTC Stock is said to be highly leveraged.
Biostem Technologies is overvalued with Real Value of 5.72 and Hype Value of 9.01. The main objective of Biostem Technologies otc analysis is to determine its intrinsic value, which is an estimate of what Biostem Technologies is worth, separate from its market price. There are two main types of Biostem Technologies' stock analysis: fundamental analysis and technical analysis.
The Biostem Technologies otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Biostem |
Biostem OTC Stock Analysis Notes
The company recorded a loss per share of 0.58. Biostem Technologies had not issued any dividends in recent years. The entity had 1:400 split on the 27th of January 2015. BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida. Biostem Technologies is traded on OTC Exchange in the United States.The quote for Biostem Technologies is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on Biostem Technologies please contact the company at 954 380 8342 or go to https://www.biostemtechnologies.com.Biostem Technologies Investment Alerts
| Biostem Technologies is way too risky over 90 days horizon | |
| Biostem Technologies appears to be risky and price may revert if volatility continues | |
| Biostem Technologies currently holds 1.32 M in liabilities. Biostem Technologies has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biostem Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Biostem Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biostem Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biostem to invest in growth at high rates of return. When we think about Biostem Technologies' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 2.52 M. Net Loss for the year was (2.39 M) with profit before overhead, payroll, taxes, and interest of 163.78 K. | |
| Biostem Technologies currently holds about 1.37 M in cash with (581.57 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. |
Biostem Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.19 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biostem Technologies's market, we take the total number of its shares issued and multiply it by Biostem Technologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 19th of February, Biostem Technologies shows the Downside Deviation of 7.2, mean deviation of 7.53, and Risk Adjusted Performance of 0.0818. Biostem Technologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Biostem Technologies, which can be compared to its peers. Please confirm Biostem Technologies jensen alpha, as well as the relationship between the potential upside and skewness to decide if Biostem Technologies is priced correctly, providing market reflects its regular price of 6.22 per share. Given that Biostem Technologies has jensen alpha of 0.8905, we suggest you to validate Biostem Technologies's prevailing market performance to make sure the company can sustain itself at a future point.Biostem Technologies Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
Biostem Technologies Outstanding Bonds
Biostem Technologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biostem Technologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biostem bonds can be classified according to their maturity, which is the date when Biostem Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BIOGEN INC 52 Corp BondUS09062XAD57 | View | |
| BIOGEN INC Corp BondUS09062XAG88 | View | |
| BIOGEN INC Corp BondUS09062XAH61 | View | |
| BIIB 325 15 FEB 51 Corp BondUS09062XAK90 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Biostem Technologies Predictive Daily Indicators
Biostem Technologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biostem Technologies otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Biostem Technologies Forecast Models
Biostem Technologies' time-series forecasting models are one of many Biostem Technologies' otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biostem Technologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Biostem Technologies Debt to Cash Allocation
Many companies such as Biostem Technologies, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Biostem Technologies currently holds 1.32 M in liabilities. Biostem Technologies has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biostem Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Biostem Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biostem Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biostem to invest in growth at high rates of return. When we think about Biostem Technologies' use of debt, we should always consider it together with cash and equity.Biostem Technologies Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Biostem Technologies' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Biostem Technologies, which in turn will lower the firm's financial flexibility.Biostem Technologies Corporate Bonds Issued
About Biostem OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Biostem Technologies prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biostem shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Biostem Technologies. By using and applying Biostem OTC Stock analysis, traders can create a robust methodology for identifying Biostem entry and exit points for their positions.
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida. Biostem Technologies is traded on OTC Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Biostem Technologies to your portfolios without increasing risk or reducing expected return.Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
Other Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.